Wells Fargo lowered the firm’s price target on AbbVie to $195 from $200 and keeps an Overweight rating on the shares. The firm is not concerned about I&I pricing rebates, as Rinvoq and Skyrizi are still expected to drive high double-digit growth, and would be a buyer of the stock here, the analyst tells investors in a research note. At the same time, pipeline concerns make Wells Fargo see the need for M&A.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABBV:
- Abbvie Earnings Update: Did it Beat Estimate Forecasts?
- AbbVie says discontinuing cystic fibrosis programs due to lack of efficacy
- Unusually active option classes on open April 27th
- AbbVie reports Q1 global Humira revenue $3.54B, down 25.2% on reported basis
- AbbVie Reports First-Quarter 2023 Financial Results